LifeMD, Inc. (NASDAQ:LFMD) CEO Sells $334,500.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CEO Justin Schreiber sold 25,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $13.38, for a total transaction of $334,500.00. Following the transaction, the chief executive officer directly owned 2,500,721 shares of the company's stock, valued at $33,459,646.98. The trade was a 0.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Justin Schreiber also recently made the following trade(s):

• On Monday, June 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $12.47, for a total transaction of $311,750.00.
• On Thursday, May 1st, Justin Schreiber sold 21,995 shares of LifeMD stock. The shares were sold at an average price of $7.53, for a total transaction of $165,622.35.
• On Tuesday, April 29th, Justin Schreiber sold 50,000 shares of LifeMD stock. The stock was sold at an average price of $7.78, for a total transaction of $389,000.00.

LifeMD Stock Performance

LFMD traded down $0.39 on Friday, hitting $12.55. 902,588 shares of the company were exchanged, compared to its average volume of 1,077,909. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $15.84. The firm has a market capitalization of $570.17 million, a P/E ratio of -36.90 and a beta of 2.40. The business's fifty day moving average is $11.34 and its 200 day moving average is $7.55.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million during the quarter, compared to analysts' expectations of $62.47 million. Analysts forecast that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LFMD. CWM LLC grew its position in shares of LifeMD by 17.5% in the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after purchasing an additional 1,351 shares during the period. Prudential Financial Inc. lifted its position in LifeMD by 19.3% during the fourth quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock worth $67,000 after buying an additional 2,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock worth $270,000 after buying an additional 2,235 shares during the last quarter. Rhumbline Advisers grew its holdings in LifeMD by 6.1% in the 4th quarter. Rhumbline Advisers now owns 48,689 shares of the company's stock valued at $241,000 after buying an additional 2,814 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of LifeMD by 26.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after acquiring an additional 2,895 shares during the last quarter. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. BTIG Research upped their price target on LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, June 18th. B. Riley upgraded shares of LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of LifeMD in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $12.00.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.